AU2017275782B2 - A vaccine in combination with an immune checkpoint inhibitor for use in treating cancer - Google Patents
A vaccine in combination with an immune checkpoint inhibitor for use in treating cancer Download PDFInfo
- Publication number
- AU2017275782B2 AU2017275782B2 AU2017275782A AU2017275782A AU2017275782B2 AU 2017275782 B2 AU2017275782 B2 AU 2017275782B2 AU 2017275782 A AU2017275782 A AU 2017275782A AU 2017275782 A AU2017275782 A AU 2017275782A AU 2017275782 B2 AU2017275782 B2 AU 2017275782B2
- Authority
- AU
- Australia
- Prior art keywords
- seq
- polypeptide
- sequence
- cancer
- immune checkpoint
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001148—Regulators of development
- A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001157—Telomerase or TERT [telomerase reverse transcriptase]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16172760.7 | 2016-06-02 | ||
| EP16172760 | 2016-06-02 | ||
| PCT/EP2017/063589 WO2017207814A1 (en) | 2016-06-02 | 2017-06-02 | A vaccine in combination with an immune checkpoint inhibitor for use in treating cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2017275782A1 AU2017275782A1 (en) | 2019-01-24 |
| AU2017275782B2 true AU2017275782B2 (en) | 2024-08-15 |
Family
ID=56132759
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2017275782A Ceased AU2017275782B2 (en) | 2016-06-02 | 2017-06-02 | A vaccine in combination with an immune checkpoint inhibitor for use in treating cancer |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US11419927B2 (OSRAM) |
| EP (2) | EP3463436B1 (OSRAM) |
| JP (2) | JP7321709B2 (OSRAM) |
| AU (1) | AU2017275782B2 (OSRAM) |
| CA (1) | CA3026172A1 (OSRAM) |
| DK (1) | DK3463436T3 (OSRAM) |
| ES (1) | ES2965957T3 (OSRAM) |
| FI (1) | FI3463436T3 (OSRAM) |
| HR (1) | HRP20231650T1 (OSRAM) |
| HU (1) | HUE065176T2 (OSRAM) |
| LT (1) | LT3463436T (OSRAM) |
| PL (1) | PL3463436T3 (OSRAM) |
| PT (1) | PT3463436T (OSRAM) |
| RS (1) | RS65007B1 (OSRAM) |
| SI (1) | SI3463436T1 (OSRAM) |
| WO (1) | WO2017207814A1 (OSRAM) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108383894A (zh) | 2010-02-16 | 2018-08-10 | 阿尔特公司 | 多肽及其应用 |
| RS65007B1 (sr) | 2016-06-02 | 2024-01-31 | Ultimovacs Asa | Vakcina u kombinaciji sa inhibitorom imunološke kontrolne tačke za primenu u lečenju kancera |
| GB201803178D0 (en) * | 2018-02-27 | 2018-04-11 | Univ Oslo Hf | Specific binding molecules for htert |
| TWI805792B (zh) * | 2018-06-29 | 2023-06-21 | 日商大鵬藥品工業股份有限公司 | 抗腫瘤劑及其評估方法 |
| CN117940152A (zh) | 2021-06-09 | 2024-04-26 | 阿尔特有限公司 | 缀合物 |
| WO2024083867A1 (en) * | 2022-10-17 | 2024-04-25 | Ultimovacs Asa | Biomarker |
| WO2024126758A2 (en) | 2022-12-14 | 2024-06-20 | Ultimovacs Ab | A nucleic acid molecule and a chimeric polypeptide |
| WO2024126737A1 (en) | 2022-12-14 | 2024-06-20 | Ultimovacs Ab | A core and a conjugate |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU784062B2 (en) | 1999-08-23 | 2006-01-19 | Dana-Farber Cancer Institute, Inc. | Novel B7-4 molecules and uses therefor |
| PT1234031T (pt) | 1999-11-30 | 2017-06-26 | Mayo Foundation | B7-h1, uma nova molécula imunoregulatória |
| ATE552849T1 (de) * | 2002-04-12 | 2012-04-15 | Medarex Inc | Behandlungsverfahren unter verwendung von ctla-4 antikörpern |
| BR0316880A (pt) | 2002-12-23 | 2005-10-25 | Wyeth Corp | Anticorpos contra pd-1 e usos dos mesmos |
| EP2439273B1 (en) | 2005-05-09 | 2019-02-27 | Ono Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
| KR101888321B1 (ko) | 2005-07-01 | 2018-08-13 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| EP2007423A2 (en) * | 2006-04-05 | 2008-12-31 | Pfizer Products Incorporated | Ctla4 antibody combination therapy |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| US8217149B2 (en) | 2008-12-09 | 2012-07-10 | Genentech, Inc. | Anti-PD-L1 antibodies, compositions and articles of manufacture |
| CN108383894A (zh) | 2010-02-16 | 2018-08-10 | 阿尔特公司 | 多肽及其应用 |
| RS55670B1 (sr) | 2010-03-15 | 2017-06-30 | Academisch Ziekenhuis Leiden | Peptidi, konjugati i metod za povećanje imunogenosti vakcine |
| WO2012037551A2 (en) | 2010-09-17 | 2012-03-22 | Irx Therapeutics, Inc. | Primary cell-derived biologic and wt1 synthetic long peptide vaccine |
| HK1212237A1 (en) | 2012-08-31 | 2016-06-10 | University Of Virginia Patent Foundation | Target peptides for immunotherapy and diagnostics |
| GB201223386D0 (en) | 2012-12-24 | 2013-02-06 | Immune Targeting Systems Its Ltd | Vaccine |
| SG10201710473VA (en) | 2013-02-22 | 2018-02-27 | Curevac Ag | Combination of vaccination and inhibition of the pd-1 pathway |
| MX369709B (es) | 2013-03-15 | 2019-11-19 | Univ Pennsylvania | Vacunación mejorada contra tirosinasa. |
| GB201315946D0 (en) | 2013-09-06 | 2013-10-23 | Immune Targeting Systems Its Ltd | Oncology vaccine |
| WO2015037000A1 (en) | 2013-09-11 | 2015-03-19 | Compugen Ltd | Vstm5 polypeptides and uses thereof as a drug for treatment of cancer, infectious diseases and immune related diseases |
| JP2017500313A (ja) | 2013-12-09 | 2017-01-05 | ブレット バイオテクノロジー， インコーポレーテッドＢｕｌｌｅｔ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ， Ｉｎｃ． | 特異的ウイルス様粒子−ＣｐＧオリゴヌクレオチドワクチンおよびその使用 |
| JP7060324B2 (ja) | 2013-12-20 | 2022-04-26 | ザ・ブロード・インスティテュート・インコーポレイテッド | ネオ抗原ワクチンによる併用療法 |
| US9903102B2 (en) | 2013-12-27 | 2018-02-27 | Xiamen Solex High-Tech Industries Co., Ltd. | Concealed embedded component for a waterway system |
| JP6581101B2 (ja) | 2014-02-14 | 2019-09-25 | イミューン デザイン コーポレイション | 局所免疫刺激及び全身免疫刺激の組み合わせによる癌の免疫療法 |
| US10933106B2 (en) | 2014-02-25 | 2021-03-02 | Deutsches Krebsforschungszentrum | RNA viruses for immunovirotherapy |
| NZ725459A (en) | 2014-05-13 | 2023-04-28 | Bavarian Nordic As | Combination therapy for treating cancer with a recombinant poxvirus expressing a tumor antigen and an immune checkpoint molecule antagonist or agonist |
| DK3142689T3 (da) | 2014-05-13 | 2021-02-15 | Bavarian Nordic As | Kombinationsbehandling til behandling af cancer med en koppevirus, som udtrykker et tumorantigen, og et monoklonalt antistof mod tim-3 |
| US20170136127A1 (en) | 2014-07-01 | 2017-05-18 | Vicus Therapeutics, Llc | Hydrogels for treating and ameliorating cancers and potentiating the immune system and methods of making and using them |
| EP3166646A4 (en) | 2014-07-07 | 2018-03-07 | Duke University | Vaccines against an oncogenic isoform of her2 (erbb2) and methods of using the same |
| US20170196952A1 (en) | 2014-07-07 | 2017-07-13 | Duke University | Vaccines against an oncogenic isoform of esr1 and methods of using the same |
| MX2017000836A (es) | 2014-07-18 | 2017-11-17 | Advaxis Inc | Composiciones inmunogenicas basadas en listeria para inducir respuestas antitumorales. |
| US10759836B2 (en) | 2014-07-18 | 2020-09-01 | University Of Washington | Cancer vaccine compositions and methods of use thereof |
| WO2016025647A1 (en) | 2014-08-12 | 2016-02-18 | Massachusetts Institute Of Technology | Synergistic tumor treatment with il-2, a therapeutic antibody, and a cancer vaccine |
| EP3209692B1 (en) | 2014-10-23 | 2024-05-22 | Institut Gustave Roussy | Methods and products for modulating microbiota composition for improving the efficacy of a cancer treatment with an immune checkpoint blocker |
| EP3215182B1 (en) | 2014-11-05 | 2023-01-04 | The Regents of The University of California | Combination immunotherapy |
| PT3405212T (pt) | 2016-01-19 | 2020-08-25 | Pfizer | Vacinas para o cancro |
| RS65007B1 (sr) | 2016-06-02 | 2024-01-31 | Ultimovacs Asa | Vakcina u kombinaciji sa inhibitorom imunološke kontrolne tačke za primenu u lečenju kancera |
| NL2017270B1 (en) | 2016-08-02 | 2018-02-09 | Aduro Biotech Holdings Europe B V | New anti-hCTLA-4 antibodies |
-
2017
- 2017-06-02 RS RS20231231A patent/RS65007B1/sr unknown
- 2017-06-02 EP EP17729078.0A patent/EP3463436B1/en active Active
- 2017-06-02 US US16/306,352 patent/US11419927B2/en active Active
- 2017-06-02 WO PCT/EP2017/063589 patent/WO2017207814A1/en not_active Ceased
- 2017-06-02 FI FIEP17729078.0T patent/FI3463436T3/fi active
- 2017-06-02 EP EP23178501.5A patent/EP4253419A3/en active Pending
- 2017-06-02 PT PT177290780T patent/PT3463436T/pt unknown
- 2017-06-02 AU AU2017275782A patent/AU2017275782B2/en not_active Ceased
- 2017-06-02 HU HUE17729078A patent/HUE065176T2/hu unknown
- 2017-06-02 HR HRP20231650TT patent/HRP20231650T1/hr unknown
- 2017-06-02 DK DK17729078.0T patent/DK3463436T3/da active
- 2017-06-02 LT LTEPPCT/EP2017/063589T patent/LT3463436T/lt unknown
- 2017-06-02 JP JP2018563076A patent/JP7321709B2/ja active Active
- 2017-06-02 SI SI201731461T patent/SI3463436T1/sl unknown
- 2017-06-02 PL PL17729078.0T patent/PL3463436T3/pl unknown
- 2017-06-02 ES ES17729078T patent/ES2965957T3/es active Active
- 2017-06-02 CA CA3026172A patent/CA3026172A1/en active Pending
-
2022
- 2022-08-09 US US17/818,584 patent/US12168045B2/en active Active
- 2022-08-24 JP JP2022132995A patent/JP2022171684A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| RS65007B1 (sr) | 2024-01-31 |
| DK3463436T3 (da) | 2023-12-18 |
| JP7321709B2 (ja) | 2023-08-07 |
| SI3463436T1 (sl) | 2024-02-29 |
| US20230049012A1 (en) | 2023-02-16 |
| WO2017207814A1 (en) | 2017-12-07 |
| PT3463436T (pt) | 2023-12-28 |
| LT3463436T (lt) | 2024-01-25 |
| JP2019517508A (ja) | 2019-06-24 |
| US12168045B2 (en) | 2024-12-17 |
| US20190247482A1 (en) | 2019-08-15 |
| EP3463436A1 (en) | 2019-04-10 |
| ES2965957T3 (es) | 2024-04-17 |
| EP4253419A2 (en) | 2023-10-04 |
| JP2022171684A (ja) | 2022-11-11 |
| EP3463436B1 (en) | 2023-09-20 |
| FI3463436T3 (fi) | 2023-12-04 |
| EP4253419A3 (en) | 2024-05-22 |
| HRP20231650T1 (hr) | 2024-05-10 |
| AU2017275782A1 (en) | 2019-01-24 |
| CA3026172A1 (en) | 2017-12-07 |
| HUE065176T2 (hu) | 2024-05-28 |
| US11419927B2 (en) | 2022-08-23 |
| PL3463436T3 (pl) | 2024-03-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12168045B2 (en) | Vaccine in combination with an immune checkpoint inhibitor for use in treating cancer | |
| US20230277641A1 (en) | Telomerase polypeptide vaccine for treating cancer | |
| US20230414735A1 (en) | Neoantigens and methods of their use | |
| KR102823333B1 (ko) | 암 치료 방법 및 조성물 | |
| CN111093691A (zh) | 蛋白质抗原及其用途 | |
| RS53872B1 (sr) | Novi i snažni mhc peptidi klase ii izvedeni iz survivina i neurokana | |
| Agarwal et al. | Development of novel immune interventions for prostate cancer | |
| TW201106962A (en) | CDC45L peptides and vaccines including the same | |
| US20060045884A1 (en) | Vaccines for autoimmune and infectious disease | |
| WO2024083866A1 (en) | Cancer treatment | |
| Thomas | Development of a prostatic acid phosphatase-derived vaccine for the treatment of advanced prostate cancer | |
| RU2773273C2 (ru) | Неоантигены и способы их использования | |
| KR20220010712A (ko) | Wt1-양성 암을 치료하기 위한 다가 면역요법 조성물 및 사용 방법 | |
| HK40029579A (en) | Protein antigens and uses thereof | |
| HK1177762A (en) | Polypeptides | |
| HK40004257A (en) | Neoantigens and methods of their use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |